Summary of Key Points
The AI pharmaceutical industry is experiencing rapid growth. On one hand, there is a severe shortage of interdisciplinary talents who understand both AI and medicine. These professionals command high salaries, but the recruitment process can take several months to a year. On the other hand, some AI pharmaceutical companies (such as Insilico Medicine) and contract research organizations (CXOs) have already reaped benefits from increased orders, leading to significant performance improvements. Traditional pharmaceutical companies are also accelerating their adoption of AI as a standard for innovation and transformation. However, the true breakthrough of the industry (the “DeepSeek moment”) is still pending the approval and launch of the first drug entirely developed by AI, as the industry is currently in a phase of validation and investment.
1. How Competitive is the AI Pharmaceutical Talent Market?
The demand for AI pharmaceutical professionals is extremely high, with salaries reaching millions of yuan per year, yet recruitment can take up to a year.
- High Salary Levels: Managers earn around 500,000 yuan per year, directors 1-1.5 million yuan, and senior positions over 2 million yuan.
- Large Talent Gap: The market demand is twice the number of available talents, and there are 4-5 times more open positions than people willing to switch jobs. Candidates are often poached before the positions can be filled (e.g., a position may remain open for 10 months without being filled because candidates are recruited multiple times).
- Challenging Talent Acquisition: Early-stage companies had to recruit from the internet for individuals who understood algorithms but not medicine, resulting in high integration costs. Now, the first batch of trained interdisciplinary talents are in high demand, but their numbers are still limited.
- Companies Face Talent Retention Challenges: Insilico Medicine increased its sales and marketing expenses by 141.7% in the first half of this year to motivate and retain talent.
2. The First Wave of Benefits Has Arrived: AI Pharmaceutical Companies and CXOs Are Profiting
Investment in AI pharmaceuticals has allowed some companies to benefit early on:
- AI Pharmaceutical Companies: Insilico Medicine reported revenue of $106 million (287.2% increase) and a net profit of $35.54 million (first half-year profit after going public), primarily from drug licensing agreements (with partners like Eli Lilly and Sanofi). Shijiazhuang Pharmaceutical Group saw a 139.2% increase in net profit due to AI platform licensing.
- CXO Companies: The need for extensive experimental validation of AI-designed candidates (synthesis, toxicology, etc.) has become a new growth area for CXOs.金斯Ray Biotech’s net profit increased by 203.3% in the first half of the year, partly due to AI-driven demand. WuXi AppTec’s AI-related business is growing rapidly, with plans for further capacity expansion.
- Impact on Experimental Resources: The demand for AI has increased the number of preclinical drug candidates and the demand for toxicology tests.
3. Traditional Pharmaceutical Companies Are Embracing AI
Traditional pharmaceutical companies are no longer hesitant and are integrating AI into their core strategies:
- Fosun Pharma: Upgraded its strategy to “completely embrace AI,” using AI tools from drug discovery to clinical data analysis. Two AI-assisted molecules have entered the preclinical stage.
- Guangyao Group: Developed a smart upgrade plan for 2026-2028, aiming to build its own pharmaceutical database and AI models to support its transformation.
- Industry Trend: AI is becoming a standard for innovative pharmaceutical companies, with high demand for positions in computational drug discovery and molecular design. Almost all innovative pharmaceutical companies are recruiting in these areas.
4. The “DeepSeek Moment” for AI Pharmaceuticals Has Not Yet Arrived
Despite the industry’s enthusiasm, the true breakthrough is still missing a critical step:
- Current Situation: No drug entirely developed by AI has been approved for market release. Moderna’s mRNA cancer vaccine used AI for antigen screening, but not for the entire development process.
- Validation Process: Insilico Medicine’s lead drug, Rentosertib, is the world’s first to complete target discovery and molecular design using AI. It is in Phase III clinical trials in China, with data expected in 2029 and a potential market launch around 2030.
- Future Challenges: The industry’s true breakthrough will depend on two key factors: the successful launch of an AI-developed drug and data proving that AI can improve R&D success rates (current traditional methods have lower success rates, while AI offers theoretical advantages, but evidence is needed).
In summary, the AI pharmaceutical industry is in a “preheating” phase, with initial benefits emerging, but the full potential has not yet been realized. Talent and technology validation remain the main challenges.